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A B S T R A C T
This is a protocol for a Cochrane Review (Intervention). The objectives are as follows:
To assess the effects of anti-TNF therapy for UMO.
B A C K G R O U N D
Description of the condition
Uveitis describes a group of disorders characterised by intraocular
inflammation. Uveitis is the fifth most common cause of visual
loss in high-income countries, accounting for approximately 10%
to 15% of total blindness (Durrani 2004; William 2007). This
figure rises to 25% in low- andmiddle-income countries (Abdulaal
2015; Rao 2013). Although uveitis may affect any age group, it
peaks in the working age population, with no significant difference
between sexes (Acharya 2013). The annual incidence of uveitis is
estimated at 17.4 to 52.4 per 100,000 people with a prevalence
of around 38 to 114.5 per 100,000 general population (Durrani
2004; Gritz 2004; Suhler 2008; William 2007).
Uveitis often occurs in younger people in the working population
compared to other eye diseases such as cataracts and age-related
macular degeneration, so the condition has a huge impact in terms
of years of potential blindness and economic cost (Durrani 2004).
Uveitis may be classified anatomically as anterior uveitis, interme-
diate uveitis, posterior uveitis or pan-uveitis (Bloch-Michel 1987;
Deschenes 2008). It may arise from a range of different infectious
and non-infectious aetiological sources. The focus of this review
is non-infectious uveitis, most of which is thought to be auto-
immune (or at least auto-inflammatory) and usually requires im-
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munosuppressive treatment (Barry 2014; VanGelder 1999). Non-
infectious uveitis may be associated with a range of inflammatory
syndromes, including ankylosing spondylitis, Behcet’s disease, sar-
coidosis and multiple sclerosis (Lee 2014a; Lee 2014b; Takeuchi
2013).
The leading cause of sight loss in people with uveitis is macular
oedema, known in this context as uveitic macular oedema (UMO)
(Durrani 2004; Lardenoye 2006). Macular oedema (MO) de-
scribes the accumulation of fluid in the retina (the light-sensitive
inner lining of the eye) in the area that provides central vision
known as the ’macula’ (Davis 2010; De Smet 2010). MO is more
common in forms of uveitis affecting themore posterior structures
in the eye, namely intermediate and posterior uveitis and pan-
uveitis; collectively these are sometimes referred to as posterior
segment-involving uveitis. MO can also occur in association with
anterior uveitis (Kaiser 2009).
Macular oedema accounts for 41% of visual impairment and 29%
of blindness in uveitis (Levin 2014; Rothova 1996). The impact
of UMO on visual acuity is usually assessed using standard dis-
tance visual acuity charts, either a Snellen chart or an Early Treat-
ment Diabetic Retinopathy Study (ETDRS) chart. Acuities from
Snellen charts are usually reported in metres in the UK and feet
in the USA. Acuities from ETDRS charts are usually reported ei-
ther as ’number of letters read’ or converted into a LogMAR frac-
tion. Although certain visual acuities are considered to be equiv-
alent (e.g. 0.0 LogMAR = 6/6 UK Snellen = 20/20 US Snellen),
these equivalences are approximate due to intrinsic differences be-
tween the charts (Kaiser 2009). Although the Snellen chart is still
widely used in clinical practice, most trials use ETDRS charts
due to various methodological advantages. Traditionally, MO has
been assessed clinically using stereoscopic slit-lamp fundus bio-
microscopy and fluorescein angiography, an invasive procedure re-
quiring intravenous dye and stereo photography imaging testing
(Brown 2004). More recently a non-invasive imaging technique,
optical coherence tomography (OCT), has become a standard
clinical practice in monitoring treatment response and follow-up
of UMO (Karim 2013; Reinthal 2004). OCT may be more sen-
sitive than clinical measures in detecting the presence of UMO
and provides accurate measures of the structural changes in term
of macular thickness (Kempen 2013).
Description of the intervention
There are a wide range of pharmacological treatments for UMO.
Corticosteroids are the mainstay of acute treatment (Davis 2010),
with alternative routes of administration including: systemic (oral,
intravenous and intramuscular); local, which includes periocu-
lar injection (sub-Tenon and orbital floor injection); and intraoc-
ular (intravitreal injection or implant) (Kok 2005; Venkatesh
2008). For long-term treatment it is important to reduce cor-
ticosteroid usage, leading to the use of ’second-line’ therapies,
which are typically immunomodulatory and include T-cell in-
hibitors (e.g. ciclosporine, and tacrolimus) and anti-metabolites
(e.g. azathioprine, methotrexate, mycophenolate mofetil). Alky-
lating agents (e.g. cyclophosphamide) have traditionally been used
as a ’third line’ for severe refractory disease (Barry 2014; Deuter
2009;Markomichelakis 2004; Neri 2008; Taylor 2009). Anti-vas-
cular endothelial growth factor (VEGF) agents and oral carbonic
anhydrase inhibitor (acetazolamide) have also occasionally been
used to treat UMO (Karim 2013). Anti-tumour necrosis factor
(anti-TNF) drugs (the subject of this review) are not licensed for
the treatment of uveitis (a feature they share with almost all treat-
ments for uveitis) but are commonly used off-licence - after the
failure of one or more second-line agents, but before the use of an
alkylating agent (Sharma 2009).
Anti-TNF drugs are biological agents that selectively block the
actions of TNF, a critical cell signalling molecule (’cytokine’) in
the inflammatory process (Deuter 2009;McCluskey 2000). Orig-
inally pioneered in the 1990s for use in rheumatoid arthritis (RA),
anti-TNF drugs are now central to the treatment of many inflam-
matory diseases including RA, juvenile idiopathic arthritis, psori-
atic arthritis, ankylosing spondylitis (AS), Crohn’s disease (Sharma
2009), and Behcet’s disease (Hatemi 2008). As noted earlier, most
non-infectious uveitis is immune mediated and is commonly as-
sociated with many of these same systemic diseases (Lee 2014a;
Lee 2014b; Murphy 2004; Takeuchi 2013).
There are currently five anti-TNF agents licensed for a range of
non-ocular inflammatory diseases; none are licensed for ocular
inflammation (Scallon 1995; Scallon 2002). The first anti-TNF
agent to be developed for clinical use was infliximab, a chimeric
IgG1 that binds to soluble and membrane TNF-α, preventing
TNF-α frombinding to its receptor in the cell (Wooley 1995). The
main route of administration is intravenous (Markomichelakis
2004). The second anti-TNF agent to reach clinical usage was
etanercept. This is a soluble protein linked to the human Fc
fragment of IgG1 that prevents TNF-α and β from interacting
with their receptor; its route of administration is subcutaneous
(Jabs 2001). The third anti-TNF drug is adalimumab, which
is a humanised IgG monoclonal antibody that binds to human
TNF-α (Kaymakcalan 2009). Adalimumab is administered sub-
cutaneously (Rudwaleit 2009). In addition to direct effects on
the TNF-pathways, downstream effects appear to include an in-
crease of regulatory T cells and modulation of vascular endothelial
growth factor (VEGF)-mediated pathways (Erckens 2011).
Golimumab is a human monoclonal antibody to TNF-α with
the advantage of requiring only monthly subcutaneous injec-
tion (Cordero-Coma 2015; Feaz 2014; Miserocchi 2014). Cer-
tolizumab consists only of the pegylated humanised Fab fragment
of a monoclonal antibody directed against TNF-α. It is adminis-
tered subcutaneously once every two weeks (Sánchez-Cano 2013;
Tlucek 2012). Both agents have shown benefits for ocular inflam-
matory disease; however, existing data are limited to case reports
and case series (Mesquida 2013).
Although patients with uveitis have received treatment with other
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anti-TNFdrugs, themost commonly used anti-TNFagents are the
monoclonal antibodies infliximab and adalimumab; in addition to
the standard systemic administration, some authors have reported
intravitreal administration (Pascual-Camps 2014; Schaap-Fogler
2014). Some patients with uveitis have also received other anti-
TNF drugs for uveitis.
How the intervention might work
The pathogenesis of the UMO is related to the underlying oc-
ular inflammatory process (uveitis) causing release of inflamma-
tory mediators including interleukin (IL)-1, IL-2, IL-6, IL-8,
and TNF-α, transforming growth factor (TGF)-β and interferon
(IFN)-γ , many of which directly or indirectly contribute to dis-
ruption of the blood-retina barrier. As a result, protein and large
molecules are trapped within the retina, causing fluid flow out
of the vessels via the osmotic gradient (Curnow 2006; Van Kooij
2006).
TNF-α, a key pro-inflammatory cytokine in a range of inflamma-
tory conditions, has proven pivotal in animal models of uveitis and
is present in intraocular fluids in human uveitis (Foxman 2002;
Murphy 2004). It is a pleiotropic cytokine produced by a number
of cells and has an important role in a range of leukocyte functions
(Feldmann 2005; Sfikakis 2004). Specific roles include: increas-
ing leukocyte recruitment to the eye via induction of chemokines
and increased leukocyte adhesion to vascular endothelium; den-
dritic cell maturation to increase the effectiveness of their antigen
presentation and cytokine production; macrophage activation and
enhancing T-cell activation. TNF-α may also be pro-apoptotic
for both infiltrating and resident cells (Cordero-Coma 2015). The
exact cascade of inflammatory mediators that leads to UMO is not
well understood (Curnow 2006; Schaap-Fogler 2014); however,
there is agreement that TNF-α upregulates VEGF production in
choroidal endothelial cells, andTNF-α blockade is associatedwith
a reduction in serum VEGF levels (Calleja 2012; Giraudo 1998;
Hangai 2006)
Why it is important to do this review
UMO is the leading cause of sight loss in uveitis and a major cause
of blindness in the working-age population. There is mechanistic
data to support the proposal that anti-TNF drugs may provide
more targeted disease control of uveitis than provided by current
non-biological therapies, and there is evidence demonstrating sig-
nificant benefit of anti-TNF drugs in related systemic inflamma-
tory conditions. Off-licence use of anti-TNF agents for uveitis has
become common in some centres, but there is a lack of national
guidelines or consensus statements and considerable variation in
practice (Davis 2010; Karim2013; Sreekantam2011). This review
will assess the effects of the anti-TNF therapy in the management
of UMO. It is timely to review the literature in order to evaluate
and summarise the available evidence for anti-TNF therapy used
for the treatment of UMO, which may form the basis of evidence-
based clinical recommendations.
O B J E C T I V E S
To assess the effects of anti-TNF therapy for UMO.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We will include all relevant randomised controlled trials (RCTs)
assessing anti-TNF therapy for treating UMO.
Types of participants
We will include trials with participants of any age, sex or ethnicity
with a diagnosis of UMO.
Types of interventions
The primary comparisons of this review will be: ·
• anti-TNF versus no treatment or placebo;
• anti-TNF versus another pharmacological agent;
• comparison of different anti-TNF drugs;
• comparison of different doses and routes of administration
of the same anti-TNF drug.
Types of outcome measures
We will not select studies based on outcomes. However, we do
consider clinical and patient-reported outcomes to be important
for the aims of the review. We will classify outcomes as primary
and secondary as follows.
Primary outcomes
The primary outcomemeasure for this reviewwill be best corrected
visual acuity (BCVA) in the treated eye. This will be measured in
the following ways.
• Mean change in LogMAR BCVA between baseline (before
treatment) and at the pre-specified time points.
• The proportion of participants gaining 5 or more ETDRS
letters (equivalent to 1 ETDRS line or 0.1 LogMAR
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improvement) at the follow-up visit in the treated eye at the pre-
specified time point.
• The proportion of participants losing 5 or more ETDRS
letters (equivalent to 1 ETDRS line or 0.1 LogMAR worsening)
recorded at the follow-up visit in the treated eye at the pre-
specified time point.
Secondary outcomes
Anatomical macular change
We will record anatomical changes in macular structure as studies
measured them.
• Mean change in central macular thickness (CMT) in
microns, as assessed by optical coherence tomography (OCT) at
pre-specified time points.
• Proportion with clinical resolution of UMO, as assessed by
stereoscopic slit-lamp fundus biomicroscopy (clinical) at pre-
specified time points.
• Proportion with angiographic resolution of UMO, as
assessed by fundus fluorescein angiography at pre-specified time
points.
Clinical estimation of vitreous haze
• Changes in vitreous haze, as assessed by stereoscopic fundus
indirect biomicroscopy examination at pre-specified time points.
Health-related quality of life
• Mean change in quality of life score (both vision-related
and non-vision related), as measured by any validated quality of
life questionnaire at the pre-specified time points
Adverse events
• We will record all adverse events reported in the included
studies at the pre-specified time points.
We expect that data will be available at multiple time points within
and between studies. We will categorise nominal data from each
analysis into three groups.Wewill group the postintervention time
points for assessment of outcomes into three different time ranges:
3 months or less, more than 3 and up to 6 months, and more than
6 months.
Search methods for identification of studies
Electronic searches
The Cochrane Eyes and Vision Information Specialist will search
the following electronic databases for randomised controlled trials
and controlled clinical trials. There will be no language or publi-
cation year restrictions.
• Cochrane Central Register of Controlled Trials
(CENTRAL) (which contains the Cochrane Eyes and Vision
Trials Register) in the Cochrane Library (latest issue) (Appendix
1);
• MEDLINE Ovid (1946 to present) (Appendix 2);
• Embase Ovid (1947 to present) (Appendix 3);
• Web of Science Conference Proceedings Citation Index-
Science (CPCI-S) (1970 to present) (Appendix 4);
• System for Information on Grey Literature in Europe
(OpenGrey) (1995 to present) (Appendix 5);
• ISRCTN registry (www.isrctn.com/editAdvancedSearch)
(Appendix 6);
• US National Institutes of Health Ongoing Trials Register
ClinicalTrials.gov (www.clinicaltrials.gov) (Appendix 7);
• World Health Organization International Clinical Trials
Registry Platform (www.who.int/ictrp) (Appendix 8);
Searching other resources
We will search the reference lists of potentially relevant studies to
identify any additional trials. We will not handsearch conference
proceedings or journals for this review.
Data collection and analysis
Selection of studies
We will carry out the study selection process in two stages.
• First, we will screen the title and the abstract of identified
articles in order to remove irrelevant records, excluding articles
that obviously do not meet the selection criteria.
• Secondly, we will retrieve the full-text of any potentially
relevant articles and assess them against the selection criteria.
At both stages, two review authors (MT and RB) will indepen-
dently assess articles, resolving any disagreements by discussion
and if required referral to a third review author (DM). Two review
authors will independently screen the titles and abstracts resulting
from the searches using web-based software (Covidence 2016).
We will illustrate the study selection processes using a PRISMA
flow diagram (Preferred Reporting Items for Systematic Reviews
and Meta-Analyses) (Moher 2010).
We will have non-English language articles translated in part or in
full to aid study selection and analysis.
Data extraction and management
See: Appendix 9.
Two review authors (MT and RB) will extract data independently
using an online data extraction form in Covidence (Covidence
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2016). We will resolve any discrepancies through discussion and
referral to a third review author (DM) if needed. We will use a
standardised piloted data extraction form. We may contact study
authors for further information. We will enter all data into Re-
view Manager 5 software (RevMan 2014). For each study, we will
extract at least the following information.
1. Study characteristics.
i) Authors, publication year, title and journal.
ii) Study design.
iii) Setting.
iv) Sample size.
v) Length of follow-up.
vi) Analysis.
2. Participant characteristics.
i) Selection/recruitment criteria.
ii) Demographic data; number, age, sex, socioeconomic
status and ethnicity.
iii) Type of uveitis (anatomical categorisation, syndrome/
aetiological classification).
iv) Comorbidity.
v) Co-medication.
3. Intervention and comparator.
i) Pharmacological agents.
ii) Regimen (dose, frequency of administration, route of
administration).
iii) Comparator details.
iv) Any difference in underlying care between treatment
group.
4. Outcomes and findings.
i) Outcomes measured and results for each outcome
including precision and statistical test results.
ii) Completeness of follow-up for each outcome.
Assessment of risk of bias in included studies
Two review authors will independently assess the quality of in-
cluded studies, resolving disagreements through discussion and
referral to a third review author (DM) if required. We will employ
the methods set out in Chapter 8 of the Cochrane Handbook for
Systematic Reviews of Intervention (Higgins 2011).
We will consider the following domains.
• Selection bias: allocation concealment bias, randomisation
sequence generation bias.
• Performance bias: masking (or blinding) of study
participants and the researcher.
• Detection bias: masking (or blinding) of outcome assessors.
• Attrition bias: loss to follow-up and rate of compliance in
both groups (withdrawals from the study lead to incomplete
outcome data).
• Reporting bias: selective outcome reporting.
We will report the risk of bias domains as being at low risk, high
risk or unclear risk (lack of information or uncertainty of potential
bias) (Higgins 2011). We will add data from the included studies
on risk of bias into RevMan 2014.
Measures of treatment effect
Continuous data
We will report continuous variables as mean differences with their
corresponding 95% confidence intervals.
Dichotomous data
We will report dichotomous variables as risk ratios (RRs) with
their corresponding 95% confidence intervals.
We are likely to present results for some outcomes using a num-
ber of different measures/statistics measured within and between
studies. For example, studies might report visual acuity in metres
or feet (from Snellen charts), a LogMAR score, or number of let-
ters or lines read (from ETDRS charts). Investigators may report
the change in acuity as a change in any one of these indices or
categorised against a threshold, for example, proportion of partic-
ipants with change greater or equal to a specific number of lines/
letters read (Kaiser 2009). Thus, different studies may consider
visual acuity to be continuous data (e.g. group mean LogMAR
score), discrete data (e.g. number of lines read) or dichotomous
data (e.g. proportion of participants reading x lines, or proportion
with a LogMAR score greater than y). it is likely that continuous
and dichotomous data will be most common. We will consider
converting data between formats to maximise the data available
for each analysis (for example, if authors state the type of chart,
we might convert letters into lines; interchange LogMAR score
and letters; and approximate Snellen UK, US and ETDRS data).
We will undertake any conversion of data with due caution, tak-
ing into account known issues (Kaiser 2009). We will explicitly
acknowledge the impact of any converted data on findings and
explore this aspect through sensitivity analysis.
We will also analyse secondary outcome measures, presenting
CMT as mean difference (MD) with 95% confidence intervals.
We will pool health-related quality of life from the same scales us-
ing mean difference, and when studies use different scales to assess
the same underlying concepts/domains, we will use standardised
mean difference.
For adverse events reported in the included studies, we will record
counts and rates. We may consider these data as continuous if the
adverse events are common and occur often (presented as mean
difference) or dichotomous data if the adverse events occur rarely
(presented as rate ratio).
Unit of analysis issues
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Clinical trials in ophthalmology may randomise one or both eyes
of participants to the intervention. The unit of randomisationmay
depend on the intervention.
• If the intervention is systemic (IV or SC) then the unit of
randomisation in the studies will be the participant.
• If the intervention is intraocular - then the unit of
randomisation could be the participant or the eye.
The unit of analysis might also depend on the outcome.
• For most outcomes related to vision, our primary unit of
analysis will be the eye.
• For outcomes related to things like quality of life. the unit
of analysis will be the participant.
• For adverse events. the unit of analysis will be the
participant (and/or the eye in case of intraocular administration).
If studies include only one eye from each participant, the unit of
analysis can either be the eye or the person. If two eyes from each
participant receive the same intervention, and authors report them
as a single unit (either through only one eye used in analysis, or
as the average outcome for the two eyes), then the unit of analysis
will be the participant.
If studies include two eyes per participant, with no differences in
treatment between eyes, and they analyse them as two eyes, the
outcome in each eye is likely to be more similar to the outcome in
the companion eye than the eye of a different participant; therefore
the study design could/should be considered as comparable to a
cluster-randomised study.
If the intervention is intraocular administration, and participants
receive different treatments in each eye (e.g. paired-eye/within-
person design), we can compare outcomes between the two eyes
and assess within-person differences if data are available. However,
if the study includes more than one eye from some participants
but not all participants, and the unit of analysis is the eye, then
we should record this, as there are issues with unit of analysis that
may not be resolvable. There is inadequate data available to know
whether the intravitreal injection of anti-TNF agents may result
in therapeutically significant systemic levels. On this basis, we will
include anywithin-person (paired-eye) studies for intravitreal anti-
TNF but report them separately.
Dealing with missing data
We will assess all the included studies for number of participants
excluded or lost to follow-up. For unclear or missing required in-
formation in study reports (e.g. on features such as study meth-
ods, outcome data, and measures of data variation), we will con-
tact study authors. However, if the authors do not respond within
four weeks or are not able to provide the additional data, we will
conduct analyses based on the best available information. We will
identify the distribution of missing data between the two arms and
discuss the potential impact of missing data on the findings of the
review.
Assessment of heterogeneity
We will assess clinical and methodological heterogeneity to deter-
mine whether studies are sufficiently similar for each comparison/
outcome to ensure that data pooling by meta-analysis is appropri-
ate (Higgins 2002; Huedo-Medina 2006). If we combine studies
in a meta-analysis, we will report the I2 statistic (which gives the
percentage of the total variability in the data due to between-study
heterogeneity) and the Tau2 statistic (which gives an estimate of
the between-study variance), where appropriate (Higgins 2011).
Assessment of reporting biases
We will examine selective outcome reporting by comparing out-
comes reported in included studies and the outcomes recorded in
study protocols. If the protocols are not publicly available, we will
contact authors to supply them. For each meta-analysis contain-
ing 10 or more studies, we will construct a funnel plot and assess
asymmetry in the plotted data (Peters 2008). Any asymmetry may
imply possible publication bias, poor reporting of small studies,
true heterogeneity or chance.
Data synthesis
Wewill assess the consistency of clinical andmethodological study
characteristics, and if there is no substantial heterogeneity between
the trials, we will combine results in a meta-analysis using a ran-
dom-effects model. If there is substantial clinical or statistical het-
erogeneity, we will not combine study results in meta-analysis but
will present data in a narrative summary.
Subgroup analysis and investigation of heterogeneity
We will consider subgroup analysis for clinical and anatomical
classification of uveitis (anterior, intermediate, posterior and pan)
where deemed appropriate.
Sensitivity analysis
We will perform sensitivity analysis to assess the robustness of the
results and the effect of excluding trials judged to have a high risk
of bias in one or more domains.
Summary of findings table
If sufficient data are available, wewill produce a ’Summary of find-
ings’ table for outcomes at six months’ follow-up to provide key
information concerning the quality of evidence, the magnitude of
effect of the interventions examined, and the sum of available data
on all of the primary and secondary outcomes for a given com-
parison. Two review authors will independently use the GRADE
tool to assess the certainty of the evidence in the included studies
6Anti-tumour necrosis factor biological therapies for the treatment of uveitic macular oedema (UMO) for non-infectious uveitis
(Protocol)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(GRADEpro 2014). We will resolve any discrepancies by discus-
sion and refer to a third review author if needed. The table of re-
sults will included the primary outcome for the review which will
be the best corrected visual acuity (BCVA) using either the mean
change in LogMAR BCVA from baseline at the pre-specified time
point or the proportion of participants gaining 5 or more ETDRS
letters from baseline BCVA. In addition, the tables will include
results for the following outcomes.
• Mean change in CMT from the baseline at the pre-specified
time point.
• Proportion of eyes with absence of dye leakage on
fluorescein angiography.
• Mean change in vitreous haze from the baseline.
• Mean change in quality of life score.
• Proportion of participants with adverse events.
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Appendix 1. CENTRAL search strategy
#1 [mh “Macular Edema”]
#2 [mh “Macula Lutea”]
#3 macula* near/3 oedema
#4 macula* near/3 edema
#5 UMO
#6 maculopath*
#7#1 or #2 or #3 or #4 or #5 or #6
#8 [mh uveitis]
#9 uveiti*
#10 iritis
#11 iridocycliti*
#12 anterior near/2 scleriti*
#13 pars planitis
#14 retinochoroidit* or choroidit*
#15 Bechet* or Vogt or Koyanagi or Harada or Fuch*
#16 [mh retinitis]
#17 retinitis or neuroretinitis
#18 uveoretinitis or uveo retinitis
#19 vitritis or panuveitis or panophthalmiti*
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#20 ophthalm* near/2 sympathetic
#21 [mh “arthritis juvenile rheumatoid”]
#22 juvenile near/2 rheumatoid near/2 arthriti*
#23 #8 or #9 or #10 or #11 or #12 or #13 or #14 or #15 or #16 or #17 or #18 or #19 or #20 or #21 or #22
#24 [mh ˆ“Tumor Necrosis Factor-alpha”]
#25 [mh ˆ“Antibodies, Monoclonal”]
#26 [mh ˆ“Antibodies, Monoclonal, Humanized”]
#27 [mh Înfliximab]
#28 [mh Âdalimumab]
#29 [mh Êtanercept]
#30 [mh ˆ“Certolizumab Pegol”]
#31 remicade* or humira* or enbrel* or golimuab* or simponi* or cimzia*
#32 #24 or #25 or #26 or #27 or #28 or #29 or #30 or #31
#33 #7 and #23 and #32
Appendix 2. MEDLINE Ovid search strategy
1. randomized controlled trial.pt.
2. (randomized or randomised).ab,ti.
3. placebo.ab,ti.
4. dt.fs.
5. randomly.ab,ti.
6. trial.ab,ti.
7. (group or groups).ab,ti.
8. or/1-7
9. exp animals/
10. exp humans/
11. 9 not (9 and 10)
12. 8 not 11
13. Macular Edema/
14. Macula Lutea/
15. (macula$ adj3 oedema).tw.
16. (macula$ adj3 edema).tw.
17. UMO.tw.
18. maculopath$.tw.
19. or/13-18
20. exp uveitis/
21. uveiti$.tw.
22. iritis.tw.
23. iridocycliti$.tw.
24. (anterior adj2 scleriti$).tw.
25. pars planitis.tw.
26. (retinochoroidit$ or choroidit$).tw.
27. (Bechet$ or Vogt or Koyanagi or Harada or Fuch$).tw.
28. exp retinitis/
29. (retinitis or neuroretinitis).tw.
30. (uveoretinitis or uveo retinitis).tw.
31. (vitritis or panuveitis or panophthalmiti$).tw.
32. (ophthalm$ adj2 sympathetic).tw.
33. arthritis juvenile rheumatoid/
34. (juvenile adj2 rheumatoid adj2 arthriti$).tw.
35. or/20-34
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36. Tumor Necrosis Factor-alpha/
37. Antibodies, Monoclonal/
38. Antibodies, Monoclonal, Humanized/
39. Infliximab/
40. Adalimumab/
41. Etanercept/
42. Certolizumab Pegol/
43. (remicade$ or humira$ or enbrel$ or golimuab$ or simponi$ or cimzia$).tw.
44. or/36-43
45. 19 and 35 and 44
46. 12 and 45
The search filter for trials at the beginning of the MEDLINE strategy is from the published paper by Glanville 2006
Appendix 3. Embase Ovid search strategy
1. exp randomized controlled trial/
2. exp randomization/
3. exp double blind procedure/
4. exp single blind procedure/
5. random$.tw.
6. or/1-5
7. (animal or animal experiment).sh.
8. human.sh.
9. 7 and 8
10. 7 not 9
11. 6 not 10
12. exp clinical trial/
13. (clin$ adj3 trial$).tw.
14. ((singl$ or doubl$ or trebl$ or tripl$) adj3 (blind$ or mask$)).tw.
15. exp placebo/
16. placebo$.tw.
17. random$.tw.
18. exp experimental design/
19. exp crossover procedure/
20. exp control group/
21. exp latin square design/
22. or/12-21
23. 22 not 10
24. 23 not 11
25. exp comparative study/
26. exp evaluation/
27. exp prospective study/
28. (control$ or prospectiv$ or volunteer$).tw.
29. or/25-28
30. 29 not 10
31. 30 not (11 or 23)
32. 11 or 24 or 31
33. exp retina macula edema/
34. eye edema/
35. (macula$ adj3 oedema).tw.
36. (macula$ adj3 edema).tw.
37. UMO.tw.
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38. maculopath$.tw.
39. or/33-38
40. exp eye inflammation/
41. uveiti$.tw.
42. iritis.tw.
43. iridocycliti$.tw.
44. (anterior adj2 scleriti$).tw.
45. pars planitis.tw.
46. (retinochoroidit$ or choroidit$).tw.
47. (Bechet$ or Vogt or Koyanagi or Harada or Fuch$).tw.
48. (retinitis or neuroretinitis).tw.
49. (uveoretinitis or uveo retinitis).tw.
50. (vitritis or panuveitis or panophthalmiti$).tw.
51. (ophthalm$ adj2 sympathetic).tw.
52. arthritis juvenile rheumatoid/
53. (juvenile adj2 rheumatoid adj2 arthriti$).tw.
54. or/40-53
55. exp tumor necrosis factor alpha/
56. antibodies, monoclonal, humanized/
57. monoclonal antibody/
58. Infliximab/
59. Adalimumab/
60. Etanercept/
61. Certolizumab Pegol/
62. (remicade$ or humira$ or enbrel$ or golimuab$ or simponi$ or cimzia$).tw.
63. or/55-62
64. 39 and 54 and 63
65. 32 and 64
Appendix 4. Web of Science CPCI search strategy
#10 #9 AND #8 AND #3
#9 TS=(Infliximab OR Adalimumab OR Etanercept OR Certolizumab NEAR/1 Pegol OR remicade* OR humira* OR enbrel* OR
golimuab* OR simponi* OR cimzia*)
#8 #4 OR #5 OR #6 OR #7
#7 TS=(vitritis OR panuveitis OR panophthalmiti* OR ophthalm* NEAR/2 sympathetic OR juvenile NEAR/2 rheumatoid NEAR/
2 arthriti*)
#6 TS=(retinochoroidit* OR choroidit* OR Bechet* OR Vogt OR Koyanagi OR Harada OR Fuch* OR retinitis OR neuroretinitis
OR uveoretinitis OR uveo NEAR/1 retinitis)
#5 TS=(pars NEAR/1 planitis OR anterior NEAR/2 scleriti*)
#4 TS=(uveiti* OR iritis OR iridocycliti*)
#3 #1 OR #2
#2 TS=(UMO OR maculopath*)
#1 TS=(macula* NEAR/3 oedema OR macula* NEAR/3 edema OR macula* NEAR/3 lutea)
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Appendix 5. OpenGrey search strategy
(macular oedema OR uveitis) AND (infliximab OR adalimumab OR etanercept OR golimumab OR certolizumab)
Appendix 6. ISRCTN search strategy
“( Condition: macular oedema OR uveitis AND Interventions: infliximab OR adalimumab OR etanercept OR golimumab OR
certolizumab )”
Appendix 7. ClinicalTrials.gov search strategy
macula edema OR uveitis | (infliximab OR adalimumab OR etanercept OR golimumab OR certolizumab)
Appendix 8. ICTRP search strategy
macular oedema OR uveitis = CONDITION AND infliximab OR adalimumab OR etanercept OR golimumab OR certolizumab =
INTERVENTION
Appendix 9. Data on study characteristics
Mandatory items Optional items
Methods
Study design ·Parallel groupRCT i.e. people randomised
to treatment
· Within-person RCT i.e. eyes randomised
to treatment
· Cluster RCT i.e. communities randomised
to treatment
· Cross-over RCT
· Other, specify
Exclusions after randomisation
Losses to follow up
Number randomised/analysed
Howweremissing data handled? e.g., avail-
able case analysis, imputation methods
Reported power calculation (Y/N), if yes,
sample size and power
Unusual study design/issues
Eyes or
Unit of randomisation/ unit of analysis
· One eye included in study, specify how
eye selected
· Two eyes included in study, both eyes
received same treatment, briefly specify
how analysed (best/worst/average/both and
adjusted for within person correlation/both
and not adjusted for within person correla-
tion) and specify if mixture one eye and two
eye
· Two eyes included in study, eyes re-
ceived different treatments, specify if cor-
rect pair-matched analysis done
Participants
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(Continued)
Country Setting
Ethnic group
Equivalence of baseline characteristics (Y/
N)
Total number of participants This information should be collected for total
study population recruited into the study. If
these data are only reported for the people who
were followed up only, please indicate.
Number (%) of men and women Number (%) of men and women
Average age and age range Average age and age range
Inclusion criteria
Exclusion criteria
Interventions
Intervention (n= )
Comparator (n= )
See MECIR 65 and 70
· Number of people randomised to this
group
· Drug (or intervention) name
· Dose
· Frequency
· Route of administration
Outcomes
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